Hong Kong · Delayed Price · Currency is HKD WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of HKD 209.29 billion. The enterprise value is 201.68 billion.
| Market Cap | 209.29B |
| Enterprise Value | 201.68B |
Important Dates
The next confirmed earnings date is Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
WuXi Biologics has 4.10 billion shares outstanding. The number of shares has decreased by -1.22% in one year.
| Current Share Class | 4.10B |
| Shares Outstanding | 4.10B |
| Shares Change (YoY) | -1.22% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 38.51% |
| Float | 3.70B |
Valuation Ratios
The trailing PE ratio is 39.49 and the forward PE ratio is 30.65. WuXi Biologics's PEG ratio is 1.65.
| PE Ratio | 39.49 |
| Forward PE | 30.65 |
| PS Ratio | 8.63 |
| PB Ratio | 3.55 |
| P/TBV Ratio | 4.16 |
| P/FCF Ratio | 70.82 |
| P/OCF Ratio | 29.66 |
| PEG Ratio | 1.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.39, with an EV/FCF ratio of 68.24.
| EV / Earnings | 36.92 |
| EV / Sales | 8.32 |
| EV / EBITDA | 22.39 |
| EV / EBIT | 27.27 |
| EV / FCF | 68.24 |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.39 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 1.17 |
| Interest Coverage | 46.46 |
Financial Efficiency
Return on equity (ROE) is 11.64% and return on invested capital (ROIC) is 12.99%.
| Return on Equity (ROE) | 11.64% |
| Return on Assets (ROA) | 6.88% |
| Return on Invested Capital (ROIC) | 12.99% |
| Return on Capital Employed (ROCE) | 12.00% |
| Weighted Average Cost of Capital (WACC) | 7.47% |
| Revenue Per Employee | 1.83M |
| Profits Per Employee | 412,168 |
| Employee Count | 13,252 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 8.11 |
Taxes
In the past 12 months, WuXi Biologics has paid 1.70 billion in taxes.
| Income Tax | 1.70B |
| Effective Tax Rate | 21.00% |
Stock Price Statistics
The stock price has increased by +66.56% in the last 52 weeks. The beta is 0.60, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +66.56% |
| 50-Day Moving Average | 38.59 |
| 200-Day Moving Average | 35.79 |
| Relative Strength Index (RSI) | 79.83 |
| Average Volume (20 Days) | 38,382,731 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of HKD 24.25 billion and earned 5.46 billion in profits. Earnings per share was 1.29.
| Revenue | 24.25B |
| Gross Profit | 11.15B |
| Operating Income | 7.40B |
| Pretax Income | 8.08B |
| Net Income | 5.46B |
| EBITDA | 8.82B |
| EBIT | 7.40B |
| Earnings Per Share (EPS) | 1.29 |
Balance Sheet
The company has 17.51 billion in cash and 3.45 billion in debt, with a net cash position of 14.05 billion or 3.42 per share.
| Cash & Cash Equivalents | 17.51B |
| Total Debt | 3.45B |
| Net Cash | 14.05B |
| Net Cash Per Share | 3.42 |
| Equity (Book Value) | 59.02B |
| Book Value Per Share | 12.72 |
| Working Capital | 22.06B |
Cash Flow
In the last 12 months, operating cash flow was 7.06 billion and capital expenditures -4.10 billion, giving a free cash flow of 2.96 billion.
| Operating Cash Flow | 7.06B |
| Capital Expenditures | -4.10B |
| Depreciation & Amortization | 1.49B |
| Net Borrowing | -2.08B |
| Free Cash Flow | 2.96B |
| FCF Per Share | 0.72 |
Margins
Gross margin is 45.98%, with operating and profit margins of 30.50% and 22.53%.
| Gross Margin | 45.98% |
| Operating Margin | 30.50% |
| Pretax Margin | 33.30% |
| Profit Margin | 22.53% |
| EBITDA Margin | 36.37% |
| EBIT Margin | 30.50% |
| FCF Margin | 11.63% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.22% |
| Shareholder Yield | 1.22% |
| Earnings Yield | 2.61% |
| FCF Yield | 1.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for WuXi Biologics is 47.54, which is -6.78% lower than the current price. The consensus rating is "Buy".
| Price Target | 47.54 |
| Price Target Difference | -6.78% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 16.94% |
| EPS Growth Forecast (3Y) | 15.84% |
Stock Splits
The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Nov 16, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 7.54 and a Piotroski F-Score of 8.
| Altman Z-Score | 7.54 |
| Piotroski F-Score | 8 |